bpc 157 tendinopathy The Hidden Risks of BPC‑157: What Patients Need to Know About Contamination and Safety Accelerating Tendon Healing: The Role

Biochem Biophys Res Commun 251(2):471476 Devic E et al (1996) Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis

BPC-157 is not FDA-approved for any medical use and is classified as a research peptide

What matters is the resulting concentration: extremely dilute solutions (under ~0.5 mg/mL) require larger injection volumes per dose, which becomes uncomfortable and can shift absorption kinetics

SMT peptides come to you as a lyophilized powder to maintain quality and integrity

The result is a 10,000mcg/mL concentration

In REDEFINE 1 (NEJM 2025, n=3,417, 68 weeks), cagrilintide monotherapy at 2.4 mg produced 11.8% mean body-weight reduction versus 2.3% with placebo